

# Rocuronium requirements on the Paediatric Intensive Care Unit: the value of monitoring neuromuscular function

<b>Submission date</b> 30/09/2004	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 30/09/2004	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 13/09/2013	<b>Condition category</b> Nervous System Diseases	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Dr Oliver Bagshaw

### Contact details

Birmingham Children's Hospital  
Department of Anaesthesia  
Steelhouse Lane  
Birmingham  
United Kingdom  
B4 6NH

## Additional identifiers

### Protocol serial number

N0045125254

## Study information

### Scientific Title

**Study objectives**

Does monitoring neuromuscular function on PICU (Paediatric Intensive Care Unit) have any advantages over standard practice of clinical assessment of neuromuscular function/drug requirements?

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration

**Study design**

Randomised controlled trial

**Primary study design**

Interventional

**Study type(s)**

Not Specified

**Health condition(s) or problem(s) studied**

Nervous System Diseases: Neuromuscular function

**Interventions**

Patients randomly allocated to received either standard management of NMBD (neuromuscular blocking drug) administration or protocol driven according to monitored neuromuscular function.

**Intervention Type**

Other

**Phase**

Not Specified

**Primary outcome(s)**

1. Total amount of NMBD administered
2. Speed of recovery or neuromuscular function once NMBDs stopped
3. Complications related to residual NM paralysis

**Key secondary outcome(s)**

Not provided at time of registration

**Completion date**

31/05/2003

**Eligibility****Key inclusion criteria**

30 patients under the age of 16 years requiring administration of Rocuronium to facilitate mechanical ventilation for more than 48 hours.

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Child

**Upper age limit**

16 years

**Sex**

Not Specified

**Key exclusion criteria**

Not provided at time of registration

**Date of first enrolment**

01/06/2002

**Date of final enrolment**

31/05/2003

**Locations****Countries of recruitment**

United Kingdom

England

**Study participating centre**

Birmingham Children's Hospital

Birmingham

United Kingdom

B4 6NH

**Sponsor information****Organisation**

Department of Health

**Funder(s)**

**Funder type**

Government

**Funder Name**

Birmingham Children's Hospital NHS Trust (UK)

## **Results and Publications**

**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration